470 / 1084
Introduction
Use of EBRT, brachytherapy, chemoradiotherapy and chemotherapy in
patients with metastatic esophageal cancer and the effect on overall survival
South of the Netherlands 1994 - 2013 (n=1020)
Bernards et al. Acta Oncol 2016
•
Median survival of M+ EC improved from 18 (1994-1998) to 25 wks (2009-2013)
•
Contributing factors: major changes in treatment strategies and better pt selection